Orion

42.78 EUR

+1.25 %

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

13,886 following

Compare

+1.25%

-3.97%

-9.35%

+8%

+8.94%

+12.73%

+19.9%

+1.71%

+280.94%

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Market cap

6.04B EUR

Turnover

20.51M EUR

P/E (adj.) (24e)

19.29

EV/EBIT (adj.) (24e)

15.2

P/B (24e)

6.17

EV/S (24e)

4.04

Dividend yield-% (24e)

3.86 %

Coverage

Recommendation

Accumulate

Target price

47.00 EUR

Updated

2024-10-30

Financial calendar

25/2

2025

Annual report '24

3/4

2025

General meeting '24

23/4

2025

Interim report Q1'25

Risk

Business risk

Valuation risk

Low

High

ShowingAll content types

Regulatory press releaseyesterday

CORRECTION: Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

Orion

Regulatory press release12/19/2024, 5:00 PM

Change in Orion Group Executive Management Board as of 1 June 2025 – Mikko Kemppainen appointed General Counsel

Orion

Drug development investment: Value creation through M&As and licensing agreements

Article12/19/2024, 11:07 AM by

Antti Siltanen

Drug development investment: Value creation through M&As and licensing agreements

The fourth part of our series of articles focusing on investing in Life Science companies deals with value creation in drug development companies through M&As and licensing agreements.

Faron Pharmaceuticals Herantis Pharma Orion Modulight

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Create account

Press release12/18/2024, 3:00 PM

Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics

Orion

Regulatory press release12/12/2024, 6:30 PM

Penalty payment to a member of Orion’s Board of Directors for delay in notifying managers’ transaction

Orion

Analyst Comment12/3/2024, 10:21 AM by

Antti Siltanen

Regulation of drug development

The third part in our series of articles on investing in Life Science companies deals with regulatory issues. Regulatory processes are demanding and time-consuming, and failure to comply can be disastrous for a drug development company.

Faron Pharmaceuticals Herantis Pharma Orion Mendus Modulight

Video12/2/2024, 2:00 PM

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia Technologies BBS-Bioactive Bone Substitutes Bioretec Biohit Faron Pharmaceuticals Modulight Nexstim Orion Bittium Detection Technology Optomed Revenio Group Nightingale Health Herantis Pharma Nanoform Finland

Regulatory press release11/27/2024, 7:00 AM

Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster

Orion

Regulatory press release9/20/2024, 6:30 AM

213,285 Orion Corporation A shares converted into B shares

Orion

Regulatory press release9/11/2024, 6:30 AM

Inside information: Orion upgrades full-year outlook for 2024

Orion

Orion

42.78

EUR